A 44-year-old Omani male presented to the Dermatology Department with a four-month history of skin lesion over the face, associated with a feeling of tightness. He reported no history of itching, oral ulceration, fever, shortness of breath, or eye symptoms. There was no history of photosensitivity. His medical and drug history were unremarkable.
plugging, and basal layer vacuolization. The dermis showed perivascular and perifollicular lymphocytic infiltrate. Staining for acid-fast bacilli was negative. A diagnosis of discoid lupus erythematosus (DLE) was made based on clinical and histopathological features. The patient was treated with regular sunblock and potent topical steroids but showed mild response after two months, so he was started on hydroxychloroquine.
D I S C U S S I O N
DLE is the most common form of chronic cutaneous lupus erythematosus (LE); other forms include LE profundus, chilblain LE, and LE tumidus. It most commonly affects women in their fourth or fifth decade, and it can present as a manifestation of systemic LE in 20% of patients. 1 DLE can be localized or generalized, with the localized form being the most common (80% of cases), which typically affects sun-exposed parts of the face like the nose, cheeks, and ear lobe. It presents initially as red or hyperpigmented plaques with adherent scales. Older lesions develop scarring, which causes loss of pigment and atrophy. A very characteristic clinical sign is called "carpet-tack sign", which refers to horny plugs occupying the hair follicles, that appear after removal of adherent surface scales. 2 The diagnosis is usually made on clinical features. A skin biopsy may be needed to confirm the diagnosis, which typically shows vacuolar alteration of the basal cell layer, thickening of the basement membrane, follicular plugging, hyperkeratosis, atrophy of the epidermis and inflammatory cell infiltrate (usually lymphocytic) in a perivascular, periappendageal, and subepidermal location. Most patients with DLE do not have any systemic or serologic abnormalities, although antinuclear antibodies may be present in about 20% of cases. 3 Treatments for DLE initially include preventive strategies (e.g. photoprotection) and topical therapies (corticosteroids and topical calcineurin inhibitors). 4 Oral antimalarials (most commonly hydroxychloroquine) is the first-line systemic treatment. Other systemic agents include systemic steroids, methotrexate, thalidomide, and azathioprine. r efer ences
